Mumbai: Glenmark Pharmaceuticals Ltd said on Tuesday SmithKline Beecham Corp has filed a lawsuit for an ANDA filing for Atovaquone and Proguanil hydrochloride tablets by its US unit.
GlaxoSmithKline currently markets its products in the US as Malarone, which is used for prevention and treatment of malaria.
With this, Glenmark has four first-to-file products under litigation under the Hatch-Waxman Act, it said in a statement to the Bombay Stock Exchange (BSE).
If Glenmark successfully challenges the patents, it will be entitled to marketing exclusivity for 180 days, it added.
Shares in Glenmark were up 3.3% at Rs256 in a firm Mumbai market.